Top Medtech Executive Tapped for His Entrepreneurial Vision and Success
Delphinus Medical Technologies,Inc., innovator and developer of SoftVue™, a whole breast ultrasound system that incorporates the first-ever ring transducer design, has named Mark J. Forchette President and Chief Executive Officer. Forchette is an accomplished medtech executive with demonstrated success transforming industries and driving breakthrough technologies to market leadership.
“The board of directors is delighted with Mark’s appointment as president and CEO,” said Paul McCreadie, managing director of Arboretum Ventures and chairman of the board of Delphinus. “He brings outstanding energy and leadership to Delphinus, a remarkable record of success, and a deep passion for introducing new technologies that improve the lives of many. Mark’s expertise and leadership bring a fresh trajectory to the organization that will benefit Delphinus greatly as we advance our regulatory and commercial objectives.”
Prior to joining Delphinus, Forchette was President and Chief Executive Officer of OptiMedica Corporation, an ophthalmic medical device company that dramatically changed the standard of care in retina, glaucoma and cataract. He led the start-up venture through development and growth, successfully completed multiple rounds of financing, and oversaw the company’s acquisition by Abbott Laboratories in 2013. He began his career in the medtech industry as a sales representative at Greishaber and Company,Inc.,where he ultimately became Vice President of U.S. Sales and Marketing and led the company through its acquisition by Alcon. During his tenure at Alcon, he steered the tactical integration of Grieshaber, advanced to vice president of Vitreoretinal Sales and Global Marketing, and led the retina portfolio through substantial market share gain.
Forchette has a bachelor’s degree in marketing from Auburn University and completed the Harvard Program for Management Development. He is currently on the Dean’s Advisory Board of the Harbert College of Business at Auburn and is a member of the board of directors of VisionCare Technologies in Saratoga, Calif.
“Delphinus’ SoftVue technology is stunning, and the opportunity to lead the team into the future is truly compelling,”said Forchette. “I have experienced how impactful transformative technologies can be in establishing a paradigm shift in both practice technique and clinical results.The imaging innovation of SoftVue is poised as that breakthrough advancement to improve breast cancer detection and diagnosis, particularly for women with dense breast tissue, where there is a true need for new technologies in breast cancer screening.”
Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a circular transducer technology to transmit and receive ultrasound signals. SoftVue™ captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast, something no other currently available ultrasound system can do. With a short scan time of one to two minutes per breast, SoftVue presents a complete image map of the whole breast, providing a consistent and uniform exam without reliance on operator skill and technique.
In recent years, it has become understood that dense breast tissue can obscure breast cancer, rendering mammography ineffective for 40 percent of women in the U.S. With growing state legislation requiring women to be notified of their breast tissue density, new non-radiation imaging solutions are needed for the health professionals engaged every day in bettering breast health.
About Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue™, the first circular array transducer technology that has received U.S. Food and Drug Administration clearance. The patented technology is a whole breast ultrasound tomography imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan. SoftVue™ is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography. For more information, visit www.delphinusmt.com.
VP, Marketing and Sales
Delphinus Medical Technologies, Inc.